Company intelligence / Profile preview
Cerium Pharmaceuticals
Gaithersburg, Maryland, United Statesceriumpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Cerium Pharmaceuticals has completed preclinical and Phase 1 studies demonstrating safety and tolerability of its lead candidate SNP-ACTH (1–39) Gel. The company received FDA Orphan Drug Designation for this product targeting PMN. It is currently enrolling patients in a multi-country Phase 3 trial comparing SNP-ACTH Gel to rituximab for first-line immunosuppressive treatment of moderate to high-risk PMN patients. No approved therapies exist for PMN, highlighting the unmet need addressed by this program[7][8][10].
- Therapeutic areas
- Nephrology
- Modalities
- Synthetic peptides (specifically synthetic ACTH)biologics[1][10]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Cerium Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cerium Pharmaceuticals.